Mesoblast closes us$110/a$138 million financing led by us strategic investor group

New york, march 08, 2021 (globe newswire) -- mesoblast limited (nasdaq:meso; asx:msb), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completion and settlement of its us$110 million private placement led by a strategic us investor group, that was announced on tuesday, march 2, 2021.
MESO Ratings Summary
MESO Quant Ranking